BioViva
BioViva is dedicated to lengthening healthy human lifespans through gene therapy, focusing on anti-aging and age-reversing treatments. They develop platforms to treat severe genetic disorders and cellular aging, aiming to make regenerative medicine accessible and affordable to the masses. Their mission is to address biological aging at its root, reducing suffering caused by age-related diseases, and to accelerate the development and testing of effective anti-aging therapies. The company has pioneered gene therapies such as telomerase activation and myostatin inhibition, and is actively involved in research, media engagement, and strategic partnerships to bring these therapies to market.
Industries
Nr. of Employees
small (1-50)
Patents
Products
Telomerase gene-delivery therapeutic candidate
A gene-delivery approach intended to induce telomerase expression in target tissues to restore aspects of youthful gene expression and support tissue regeneration.
Myostatin-inhibition gene-delivery therapeutic candidate
A gene-delivery candidate encoding a myostatin-inhibiting protein to increase muscle mass and strength for sarcopenia and muscular dystrophy indications.
Multi-modal biomarkers and analysis package
Packaged set of molecular, physiological, anatomical, clinical, and qualitative biomarkers combined with an analytical pipeline to quantify biological age and treatment response.
Telomerase gene-delivery therapeutic candidate
A gene-delivery approach intended to induce telomerase expression in target tissues to restore aspects of youthful gene expression and support tissue regeneration.
Myostatin-inhibition gene-delivery therapeutic candidate
A gene-delivery candidate encoding a myostatin-inhibiting protein to increase muscle mass and strength for sarcopenia and muscular dystrophy indications.
Multi-modal biomarkers and analysis package
Packaged set of molecular, physiological, anatomical, clinical, and qualitative biomarkers combined with an analytical pipeline to quantify biological age and treatment response.
Services
Design of adaptive protocols and statistical plans for early-stage gene and cell therapy studies to accelerate human testing and iterative evaluation.
Pre- and post-treatment testing using a multi-modal biomarker panel with downstream bioinformatics analysis to quantify biological aging and treatment effects.
Coordination of patient access and trial conduct through partner clinical networks, including alternative patient-funded participation models and partner clinics for enrollment and delivery.
Provision and curation of an open-access gene therapy database and tools for researchers and organizations to explore gene therapy designs and standards.
Advisory and planning services for bioreactor-based production and mass-manufacturing strategies to increase vector yield and reduce per-unit cost.
Design of adaptive protocols and statistical plans for early-stage gene and cell therapy studies to accelerate human testing and iterative evaluation.
Pre- and post-treatment testing using a multi-modal biomarker panel with downstream bioinformatics analysis to quantify biological aging and treatment effects.
Coordination of patient access and trial conduct through partner clinical networks, including alternative patient-funded participation models and partner clinics for enrollment and delivery.
Provision and curation of an open-access gene therapy database and tools for researchers and organizations to explore gene therapy designs and standards.
Advisory and planning services for bioreactor-based production and mass-manufacturing strategies to increase vector yield and reduce per-unit cost.
Expertise Areas
- Viral vector platform development
- Telomerase-based therapeutic approaches
- Myostatin-inhibition therapeutics for muscle wasting
- Combination gene and cell therapy strategies
Key Technologies
- AAV vectors
- High-capacity viral vectors
- Telomerase gene delivery
- Myostatin-inhibition constructs
News & Updates
A discussion on whether aging can be considered an engineering problem, exploring the possibilities of engineering solutions to aging.
An article discussing the potential of human life extension and the future of aging research.
An exploration of brain health and the impact of aging on cognitive functions.
A metaphorical discussion on the costs and benefits of actions and inactions in health and aging.
An overview of the biological processes involved in aging and how gene therapy can potentially reverse or slow these processes.
Details on how gene therapy, especially telomerase activation, can be used to address age-related decline and diseases.
A discussion on whether aging can be considered an engineering problem, exploring the possibilities of engineering solutions to aging.
An article discussing the potential of human life extension and the future of aging research.
An exploration of brain health and the impact of aging on cognitive functions.
A metaphorical discussion on the costs and benefits of actions and inactions in health and aging.
An overview of the biological processes involved in aging and how gene therapy can potentially reverse or slow these processes.
Details on how gene therapy, especially telomerase activation, can be used to address age-related decline and diseases.